Vizgen co-founder David Walt, a professor at Harvard Medical School, has invested in the spinout as part of its series B round.
Vizgen, a US-based single-cell spatial genomics information technology developer spun out of Harvard University, has raised $37m in a series B round featuring one of its co-founders, Prof David Walt.
Novalis LifeSciences and Northpond Ventures co-led the round, which also attracted Arch Venture Partners, Tao Capital Partners, Pure Vida Investments and an unnamed US endowment fund.
Vizgen is working on genomic profiling tools that allow massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
The series B capital has been allocated to commercialisation activities and bolstering manufacturing capacity as Vizgen prepares for a commercial release of its platform this summer.
Marijn Dekkers, chairman and founder of Novalis, will join the board of directors.
Terry Lo, president and CEO of Vizgen said: “We are at an incredibly important inflection point in the evolution of genomics. The acceleration of data and new insights that can be generated through spatial information are truly profound.
“Funding from this series B will enable us to bring the best tools for in situ single cell spatial genomics to the research community faster. We are grateful to have such supportive investors and founders to help realize this mission.”
Vizgen launched in January 2020 with $14m in series A funding co-led by Arch Venture Partners and Northpond Ventures.
